Phosphate in Biological Technology
Navigation Links
Phosphate in Biological Technology
... to that reported for other currently marketed phosphate binders. There was no increase in serum calcium ... suggest that Zerenex is an effective, tolerated phosphate binder that will potentially make a significant ... significant market potential for the drug in the phosphate binder space." Mr. Bentsur continued, "We're ...
... laboratory values, and treatment prevalence with phosphate binders, Nutritional Vitamin D, Active Vitamin D ... patients tend to be initiated on phosphate binder monotherapy when phosphorus reaches 5.7 ... can result in lower doses of Vitamin D and phosphate binders, the converse is actually true. Patients ...
... they generally treat hyperphosphatemia by taking phosphate binders, such as FOSRENOL(R) (lanthanum carbonate), at meals. phosphate binders "soak up" phosphorus in the ... comply with their prescribed dialysis, diet, and phosphate binder treatment. The dietary tips that will ...
... will meet Tuesday to consider the use of phosphate binders in patients with chronic kidney disease ... asked the three companies that currently market phosphate binders for patients on dialysis to provide ... its approach to extending the use of phosphate binders to pre- dialysis patients. In a briefing ...
... drug in Japan. The drug, an iron- based phosphate binder for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end stage renal disease, ... and commercialization costs in Japan. phosphate retention and the resulting hyperphosphatemia in ...
... citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. Keryx is also developing ...
... citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also ...
... citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also ...
... citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. The Company is ...
... citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. We are also ...
... citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also ...
... particularly in their role recommending and reinforcing adherence with phosphate Binders, Active Vitamin D, and Calcimimetic agents. In the phosphate binder market, the introduction of Genzyme's Renvela has given overall ...
... the product, feel it has a dosing and administration advantage. In the phosphate binder market, the launch of Genzyme's Renvela is beginning to shift ... share, for the first time, overall satisfaction among the various phosphate binders is highest for Shire's Fosrenol. Concern with lanthanum absorption ...
... Renal Drugs Advisory Committee recommended by a majority vote the use of phosphate binders, including FOSRENOL, to treat hyperphosphatemia in CKD stage 4 ... in 2006 (2006: $40.2 million). FOSRENOL's average market share of the US phosphate binder market increased from 8.5% in 2006 to 8.6% in 2007. The increase in ...
... indicating that they are "not at all familiar" with the product. In the phosphate binder market, nephrologists seem to be in agreement about the importance ... maintaining its position as market leader. While perceived need for a new phosphate binder is high, knowledge of new binders in development is low. Genzyme ...
... Putty to complement the existing 5cc and 10cc sizes. Both products are bone substitute materials based on ETEX's proprietary nanocrystalline calcium phosphate technology. (Logo: http://www.newscom.com/cgi-bin/prnh/20080424/NETH117LOGO ) Beta-bsm(TM) and Gamma-bsm(TM) set hard to provide ...
... the year to December 31, 2008 were up 38% to $85.9 million compared to 2007 (2007: $62.1 million). FOSRENOL's average prescription share of the US phosphate binder retail market decreased to 8.1% for the year to December 31, 2008 (2007: 8.6%). Product sales increased despite the decrease in prescriptions ...
... share from American Regent's/Fresenius Medical Care's Venofer and Watson's Ferrlecit. Many potential new products are also on the horizon in the phosphate binder market, albeit longer term. New products will likely be welcome additions as Nephrologists report that over one-third of their patients are ...
... patients and report that at any given time more than one-third of their dialysis patients are above the target level for phosphorus. Calcium based phosphate binders are the most frequently prescribed binders in both dialysis and CKD, however, there is a high prevalence of combination binder therapy ...
Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
... U.S. commercial rights to Oforta(TM) (fludarabine phosphate film-coated tablets), an oral B-cell chronic ... and safety of orally administered fludarabine phosphate relative to intravenously administered fludarabine phosphate have not been performed. The most common adverse ...... laboratory values, and treatment prevalence with phosphate binders, Nutritional Vitamin D, Active Vitamin D ... patients tend to be initiated on phosphate binder monotherapy when phosphorus reaches 5.7 ... can result in lower doses of Vitamin D and phosphate binders, the converse is actually true. Patients ...
MIT virus battery could power cars, electronic devices
... (carbon nanotubes in this case), each iron phosphate nanowire can be electrically "wired" to ... percolating throughout the electrodes to the iron phosphate and transferring energy in a very short time. ... higher voltage and capacitance, such as manganese phosphate and nickel phosphate, said Belcher. Once that ...Frost & Sullivan Recognizes ApaTech's Leadership in Orthopedic Biologics
... Silicate ions are used to selectively replace phosphate groups in the calcium phosphate crystal lattice. This new material accelerates ... graft material. The silicate substituted calcium phosphate material also displays excellent porosity at all ...Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
... GENZ ) today announced the U.S. launch of the phosphate binder Renvela(R) (sevelamer carbonate) for ... (sevelamer hydrochloride), the most-prescribed phosphate binder in the United States. It is a calcium-free, metal-free, non-absorbed phosphate binder and is available in the U.S. as 800mg ...... they generally treat hyperphosphatemia by taking phosphate binders, such as FOSRENOL(R) (lanthanum carbonate), at meals. phosphate binders "soak up" phosphorus in the ... comply with their prescribed dialysis, diet, and phosphate binder treatment. The dietary tips that will ...
... will meet Tuesday to consider the use of phosphate binders in patients with chronic kidney disease ... asked the three companies that currently market phosphate binders for patients on dialysis to provide ... its approach to extending the use of phosphate binders to pre- dialysis patients. In a briefing ...
... drug in Japan. The drug, an iron- based phosphate binder for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end stage renal disease, ... and commercialization costs in Japan. phosphate retention and the resulting hyperphosphatemia in ...
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
... citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. Keryx is also developing ...... citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. Keryx is also developing ...
Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
... citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also ...... citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also ...
... citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also ...
... citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. The Company is ...
... citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. We are also ...
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
... citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also ...... citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also ...
Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
... citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also ...Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
... citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also ...... particularly in their role recommending and reinforcing adherence with phosphate Binders, Active Vitamin D, and Calcimimetic agents. In the phosphate binder market, the introduction of Genzyme's Renvela has given overall ...
... the product, feel it has a dosing and administration advantage. In the phosphate binder market, the launch of Genzyme's Renvela is beginning to shift ... share, for the first time, overall satisfaction among the various phosphate binders is highest for Shire's Fosrenol. Concern with lanthanum absorption ...
Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
... citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. The Company is ...... Renal Drugs Advisory Committee recommended by a majority vote the use of phosphate binders, including FOSRENOL, to treat hyperphosphatemia in CKD stage 4 ... in 2006 (2006: $40.2 million). FOSRENOL's average market share of the US phosphate binder market increased from 8.5% in 2006 to 8.6% in 2007. The increase in ...
... indicating that they are "not at all familiar" with the product. In the phosphate binder market, nephrologists seem to be in agreement about the importance ... maintaining its position as market leader. While perceived need for a new phosphate binder is high, knowledge of new binders in development is low. Genzyme ...
FDA Approves Genzyme's Renvela(TM) for Dialysis Patients
... version of Renagel(R) (sevelamer hydrochloride), the most-prescribed phosphate binder in the United States. "Since its approval in 1998, Renagel has ... benefit of significant LDL cholesterol reduction. Sevelamer is the only phosphate binder available that does not contain either calcium or a metal. It has ...Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
... as the product entered new countries, and continued to grow in countries entered in the last two years. In the US, FOSRENOL's average share of the phosphate binder market in Q2 2009 declined to 7.8% (2008: 8.2%) due to a 3% decrease in prescriptions. However, US product sales grew 15% as price increases ...Phosphagenics Announces Completion of Transdermal Patch Prototypes
... products. Phosphagenics' core technology is built around the science and application of phosphorylation, a process where the addition of a phosphate group has been found to enhance the bioavailability, activity and safety of existing pharmaceuticals and nutraceuticals, as well as to assist in the ...Shire begins the year with a strong performance
... increased as the product entered new countries, and continued to grow in countries entered in the last two years. FOSRENOL's average share of the US phosphate binder market decreased to 7.8% (2008: 8.2%) and despite a 2% decrease in prescriptions product sales increased, primarily due to price increases. ...Dow AgroSciences Confirms Efficacy of Zinc Finger Nucleases for Precise Genome Modification in Maize
... biosynthesis of phytate, a component of feed corn that is particularly difficult to digest for certain animals like pigs and chickens causing excess phosphate presence in the environment. Research results confirmed the herbicide tolerance gene was inserted into the specified domain without random ...... Putty to complement the existing 5cc and 10cc sizes. Both products are bone substitute materials based on ETEX's proprietary nanocrystalline calcium phosphate technology. (Logo: http://www.newscom.com/cgi-bin/prnh/20080424/NETH117LOGO ) Beta-bsm(TM) and Gamma-bsm(TM) set hard to provide ...
Publication of Shire plc's Annual Report 2008
... kidney disease ('CKD') Following the FDA Cardiovascular and Renal Drugs Advisory Committee recommendation in October of 2007 on the use of phosphate binders, including FOSRENOL, to treat hyperphosphatemia in pre-dialysis CKD patients, Shire continues to work with the FDA to determine whether ...... the year to December 31, 2008 were up 38% to $85.9 million compared to 2007 (2007: $62.1 million). FOSRENOL's average prescription share of the US phosphate binder retail market decreased to 8.1% for the year to December 31, 2008 (2007: 8.6%). Product sales increased despite the decrease in prescriptions ...
ETHEX Corporation Issues Nationwide Voluntary Recall of Products
... 065-26) Diltiazem HC1 Capsules, 420mg (58177-066-09 & 066-11) Diltiazem HC1 Capsules, 420mg (58177-066-19 & 066-26) Disopyramide phosphate ER Capsules, 150mg (58177-002-04) Doxazosin Mesylate Tablets, 1mg (58177-266-04 & 266-08) Doxazosin Mesylate Tablets, 2mg (58177-267-04 ...Progentix Orthobiology and NuVasive Sign Investment Agreement
... and allows the near term commercialization of these products." The Progentix product portfolio currently consists of a novel family of calcium phosphate synthetic bone substitutes. The Progentix granules have demonstrated osteoinductive-like properties in preclinical models and require FDA clearance ...... share from American Regent's/Fresenius Medical Care's Venofer and Watson's Ferrlecit. Many potential new products are also on the horizon in the phosphate binder market, albeit longer term. New products will likely be welcome additions as Nephrologists report that over one-third of their patients are ...
BioLife Solutions Completes Safety Studies on HypoThermosol(R) and CryoStor(TM)
... Intravenous Injection of Biopreservation Solutions as a Vehicle for Cellular Products ," evaluated injections of HypoThermosol, CryoStor, or control phosphate buffered saline (PBS) into healthy rodents. The study was designed to mimic human clinical applications where stem cells isolated from cord or ...Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million
... Acanya(TM) On October 23, 2008, the Food and Drug Administration approved the Dow NDA for a combination product, Acanya(TM) Gel (clindamycin phosphate 1.2% and benzoyl peroxide 2.5%), indicated for the treatment of mild to moderate acne vulgaris in patients 12 years and older. About Valeant ...... patients and report that at any given time more than one-third of their dialysis patients are above the target level for phosphorus. Calcium based phosphate binders are the most frequently prescribed binders in both dialysis and CKD, however, there is a high prevalence of combination binder therapy ...
Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
... including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated ...Other ContentstradetradetradetradetradetradepatientpatientpatientpatientpatientpatientpatientpatientpatientpatientpersonalizedpersonalizedpersonalizedpersonalizedpersonalizedpersonalizedbagbagbagbagbagpainpainpainpainpainpainpainpainpainphantomtechniciantechniciantechniciantechniciantechnicianOther TagsPigtailRitlengPunctal
(Date:11/24/2009)...upus Research Institute (LRI) today named 12 new g...6 million, recognize innovative work across a broa...r their creativity, novelty, and potential to driv...t, and cure the complex disease of systemic lupus....d lupus researchers across the nation and include ...
(Date:11/24/2009)...ger and the American College of Medical Toxicology... the publication of the Journal of Medical Toxico...inning in March 2010. It was previously published... Journal of Medical Toxicology , an international... the science and practice of medical toxicology. ...
(Date:11/24/2009)... release is available in Spanish . , The pr... levels of inflammatory substances in the blood, h... shown by a research project of the University of ...cientist at the School of Pharmacy. , The projec... in relation to the control of body weight and inf...
Breaking Biology News(10 mins):Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3Springer and the American College of Medical Toxicology to work together 2It can be predicted the reaction obese patients will have to a diet 2US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 1US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 2US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 3US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 4US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 5US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 6US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 7New biofactories produce rare healing substances in the endangered Devils claw plant 54597 1New biofactories produce rare healing substances in the endangered Devils claw plant 54597 2New biofactories produce rare healing substances in the endangered Devils claw plant 54597 3Newly found DNA catalysts cleave DNA with water molecule 9589 1Newly found DNA catalysts cleave DNA with water molecule 9589 2(Date:11/28/2009)...fenders were more likely to consider change after ..., , FRIDAY, Nov. 27 (HealthDay News) -- A...sider why they should stop their dangerous behavio..., researchers have found. , The new study inclu...le-impaired convictions, who were randomly assigne...
(Date:11/27/2009)..., KELOWNA, BC, Nov. 27 /PRNewswire/ - Uploadable U...ng prime time in wellness. A combination of advanc...upload are solving a long term concern over the ac... accurately gauge and reward improved participatio...ies is one of the first wellness suppliers to inte...
(Date:11/27/2009)..., ROCHESTER, N.Y., Nov. 27 /PRNewswire-USNewswire...h care provider and fortunately every year, new va...tion. But do all vaccines boost immunity for the s...al ,booster shots, needed to keep immunity strong?...Journal of the American Academy of Pediatrics, Mic...
(Date:11/27/2009)...nd cycling plus low-emission vehicles may reduce f..., FRIDAY, Nov. 27 (HealthDay News) -- Encouraging ... cars would offer much greater public health benef...U.K. researchers have found. , The study compar...tive urban land transport scenarios for London, En...
(Date:11/27/2009)... Multi-purpose bilingual coloring ... for use by the business community to educate - in...bjects from Safety issues to Dinosuars to ABC,S an... Saint Louis, MO (PRWEB) November 27, 2009 -- To...ics or toys to keep them busy any hour of the day,...
Breaking Medicine News(10 mins):Health News:Drunk Drivers May Respond to Brief Motivational Interview 2Health News:New USB technology adds accountability and convenience to wellness programs 2Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2[1] Drunk Drivers May Respond to Brief Motivational Interview[0] New USB technology adds accountability and convenience to wellness programs[0] Why Some Vaccines May Require A Booster[0] More Foot Power, Less Car Pollution Best for Health[2] Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books
PerforatedEndonasalPigtailRitlengGoldbergPunctalPtoseBioceramicTransnasalGeuderUltraSpearOrthoPilotSIREMOBILEspion
Other Tagslikelihood 2likelihood 3likelihood 4likelihood 5likelihood 6likelihood 7likelihood 8likelihood 9likelihood 10consequences 2consequences 3consequences 4consequences 5consequences 6consequences 7consequences 8consequences 9consequences 10raising 2raising 3raising 4raising 5raising 6raising 7raising 8raising 9raising 10discuss 2discuss 3discuss 4discuss 5discuss 6discuss 7discuss 8discuss 9discuss 10board 2board 3board 4board 5board 6board 7board 8board 9board 10androgen 2span 2span 3restriction 2dioxide 2dioxide 3dioxide 4dioxide 5dioxide 6carbon 2carbon 3carbon 4carbon 5carbon 6carbon 7carbon 8carbon 9carbon 10connect 2connect 3connect 4connect 5
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |